AR065075A1 - Vectores para la expresion multiple de genes - Google Patents
Vectores para la expresion multiple de genesInfo
- Publication number
- AR065075A1 AR065075A1 ARP080100356A ARP080100356A AR065075A1 AR 065075 A1 AR065075 A1 AR 065075A1 AR P080100356 A ARP080100356 A AR P080100356A AR P080100356 A ARP080100356 A AR P080100356A AR 065075 A1 AR065075 A1 AR 065075A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- acid molecule
- vector
- polypeptide
- homology percentage
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 9
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 11
- 108020004707 nucleic acids Proteins 0.000 abstract 10
- 102000039446 nucleic acids Human genes 0.000 abstract 10
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 241001631646 Papillomaviridae Species 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07360019 | 2007-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065075A1 true AR065075A1 (es) | 2009-05-13 |
Family
ID=39522406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100356A AR065075A1 (es) | 2007-05-15 | 2008-01-29 | Vectores para la expresion multiple de genes |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8337859B2 (https=) |
| EP (1) | EP2162544B1 (https=) |
| JP (1) | JP5474767B2 (https=) |
| KR (1) | KR101514473B1 (https=) |
| CN (1) | CN101688223B (https=) |
| AR (1) | AR065075A1 (https=) |
| AU (1) | AU2008250520B2 (https=) |
| BR (1) | BRPI0810305A2 (https=) |
| CA (1) | CA2686772C (https=) |
| ES (1) | ES2416361T3 (https=) |
| IL (1) | IL201963A (https=) |
| MX (1) | MX2009012272A (https=) |
| PE (1) | PE20090483A1 (https=) |
| RU (1) | RU2462513C2 (https=) |
| TW (1) | TW200844231A (https=) |
| WO (1) | WO2008138648A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200844230A (en) * | 2007-05-15 | 2008-11-16 | Transgene Sa | Signaling peptides |
| WO2010085660A2 (en) | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| RU2555346C2 (ru) * | 2009-08-07 | 2015-07-10 | Трансген Са | Композиция для лечения инфекции вирусом гепатита в |
| EP2558116B2 (de) * | 2010-04-16 | 2020-01-08 | General Vectors GmbH | Mittel zur lokalen behandlung von zervixdysplasien |
| GB201016471D0 (en) * | 2010-09-30 | 2010-11-17 | Isis Innovation | Viral vector immunogenic compositions |
| US9216213B2 (en) * | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| WO2013112549A1 (en) | 2012-01-24 | 2013-08-01 | Sanford Research/USD | Polynucleotides for treating oncogenic viral polypeptide positive tumors |
| JP2016513115A (ja) * | 2013-02-21 | 2016-05-12 | チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド | ワクチン組成物 |
| CN107429289A (zh) * | 2014-10-14 | 2017-12-01 | 宾夕法尼亚大学理事会 | 用于癌症治疗的联合疗法 |
| IL260030B2 (en) | 2016-01-08 | 2025-12-01 | Nykode Therapeutics ASA | Therapeutic anticancer neoepitope vaccine |
| JP7053491B2 (ja) * | 2016-05-02 | 2022-04-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 治療用ｈｐｖワクチン組み合わせ |
| WO2018060288A1 (en) * | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| EP3461497A1 (en) * | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| EP4079750A3 (en) | 2018-11-21 | 2023-01-04 | Mayo Foundation for Medical Education and Research | Adenoviruses and methods for using adenoviruses |
| KR20240086779A (ko) * | 2022-12-05 | 2024-06-19 | 경상국립대학교산학협력단 | 다중 단백질의 발현을 위한 신규 핵산 구조체 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| DE69828284T2 (de) | 1997-06-30 | 2005-12-08 | Nippon Kayaku K.K. | Naphthyridinderivate oder salze davon |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| FR2774699B1 (fr) * | 1997-11-17 | 2003-10-03 | Rhone Poulenc Rorer Sa | Methode de reduction des evenements de recombinaison homologue |
| EP1212358B1 (en) * | 1999-08-25 | 2004-12-15 | Merck & Co., Inc. | Synthetic papillomavirus genes optimized for expression in human cells |
| US7001995B1 (en) | 1999-08-25 | 2006-02-21 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
| CA2457890A1 (en) | 2001-08-23 | 2003-03-06 | Merck & Co., Inc. | Vaccine using papillomavirus e proteins delivered by viral vector |
| ATE315660T1 (de) * | 2002-05-16 | 2006-02-15 | Bavarian Nordic As | Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva) |
| CL2008000249A1 (es) * | 2007-01-30 | 2008-05-30 | Transgene Sa | Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus |
-
2008
- 2008-01-29 RU RU2009144898/10A patent/RU2462513C2/ru active
- 2008-01-29 AR ARP080100356A patent/AR065075A1/es not_active Application Discontinuation
- 2008-01-29 BR BRPI0810305A patent/BRPI0810305A2/pt not_active Application Discontinuation
- 2008-01-29 ES ES08708348T patent/ES2416361T3/es active Active
- 2008-01-29 KR KR1020097023308A patent/KR101514473B1/ko not_active Expired - Fee Related
- 2008-01-29 US US12/599,971 patent/US8337859B2/en not_active Expired - Fee Related
- 2008-01-29 EP EP08708348.1A patent/EP2162544B1/en not_active Not-in-force
- 2008-01-29 CN CN200880016061XA patent/CN101688223B/zh not_active Expired - Fee Related
- 2008-01-29 AU AU2008250520A patent/AU2008250520B2/en not_active Ceased
- 2008-01-29 WO PCT/EP2008/051031 patent/WO2008138648A1/en not_active Ceased
- 2008-01-29 PE PE2008000210A patent/PE20090483A1/es not_active Application Discontinuation
- 2008-01-29 MX MX2009012272A patent/MX2009012272A/es active IP Right Grant
- 2008-01-29 TW TW097103228A patent/TW200844231A/zh unknown
- 2008-01-29 CA CA2686772A patent/CA2686772C/en not_active Expired - Fee Related
- 2008-01-29 JP JP2010507858A patent/JP5474767B2/ja not_active Expired - Fee Related
-
2009
- 2009-11-05 IL IL201963A patent/IL201963A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2416361T3 (es) | 2013-07-31 |
| PE20090483A1 (es) | 2009-05-20 |
| KR101514473B1 (ko) | 2015-04-22 |
| RU2009144898A (ru) | 2011-06-20 |
| US8337859B2 (en) | 2012-12-25 |
| IL201963A0 (en) | 2011-08-01 |
| JP5474767B2 (ja) | 2014-04-16 |
| MX2009012272A (es) | 2009-12-01 |
| KR20100019432A (ko) | 2010-02-18 |
| RU2462513C2 (ru) | 2012-09-27 |
| EP2162544B1 (en) | 2013-04-17 |
| JP2010526547A (ja) | 2010-08-05 |
| WO2008138648A1 (en) | 2008-11-20 |
| US20100303838A1 (en) | 2010-12-02 |
| HK1135731A1 (en) | 2010-06-11 |
| AU2008250520A1 (en) | 2008-11-20 |
| CA2686772A1 (en) | 2008-11-20 |
| BRPI0810305A2 (pt) | 2018-07-10 |
| TW200844231A (en) | 2008-11-16 |
| CN101688223B (zh) | 2013-07-31 |
| CA2686772C (en) | 2015-03-24 |
| CN101688223A (zh) | 2010-03-31 |
| EP2162544A1 (en) | 2010-03-17 |
| AU2008250520B2 (en) | 2013-10-31 |
| IL201963A (en) | 2013-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065075A1 (es) | Vectores para la expresion multiple de genes | |
| CL2019003842A1 (es) | Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas. | |
| MX2020005458A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| AR065350A1 (es) | Moleculas de acido nucleicos que codifican una alternanosucrasa truncada | |
| GB201201178D0 (en) | Novel enzymes | |
| MX2020003092A (es) | Vectores de adn no integrantes para la modificacion genetica de celulas. | |
| EA201101553A1 (ru) | Полипептид, деградирующий углеводы, и его применения | |
| MX2012015139A (es) | Polipéptido que tiene o que ayuda en la actividad de degradación del material de carbohidratos y usos del mismo. | |
| ES2543203T3 (es) | Grupo de genes NRPS-PKS, su manipulación y su utilidad | |
| AR090417A1 (es) | Plantas resistentes al glifosato y metodos asociados | |
| BRPI0806578A8 (pt) | Promotores de lactococcus e usos dos mesmos | |
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| NZ592082A (en) | Promoters for recombinant viral expression | |
| MY176331A (en) | Carbohydrate degrading polypeptide and uses thereof | |
| MX2014007233A (es) | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. | |
| NZ704191A (en) | Cell-penetrating peptides and uses therof | |
| BR112012029588A2 (pt) | materiais biológicas relacionados a her3. | |
| BR122019005253A8 (pt) | Molécula de ácido nucleico recombinante, vetor, célula hospedeira, polipeptídeo recombinante com atividade pesticida, composição, bem como métodos para o controle de uma população de pragas para matar uma praga, para a produção de um polipeptídeo com atividade pesticida, para a proteção de uma planta de uma praga, e para aumentar o rendimento em uma planta | |
| BR112014022166A2 (pt) | gene da delta-endotoxina axmi345 e métodos para a sua utilização | |
| AR072022A1 (es) | Genes involucrados en biosintesis de flavonoides en plantas | |
| MX2020005649A (es) | Synpiii, un promotor para la expresion especifica de genes en el epitelio pigmentario retiniano. | |
| HK1198170A1 (en) | Pseudomonas exotoxin a with less immunogenic b cell epitopes | |
| BRPI0806252B8 (pt) | molécula de ácido nucléico de promotor, vetor recombinante, célula de hospedeiro e método de expressão de gene alvo | |
| EA201590794A8 (ru) | Рекомбинантные нейротоксины clostridium botulinum | |
| PH12015500771A1 (en) | Novel fc gamma receptor iib variants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |